Data powered by Alphabet Inc.
Glenmark Pharmaceuticals
GLENMARK
₹ 1,435.60
₹ 11.00
0.77%
Glenmark Pharmaceuticals Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 67,528 |
| Weekly | 1.81% | 21,06,007 |
| Monthly | 16.80% | 1,25,53,755 |
Glenmark Pharmaceuticals Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| GLENMARK | - | 1.81% | 16.80% |
| Index | - | - | - |
| Peer Avg. | - | 5.42% | 11.51% |
*Avg of index constituents
Glenmark Pharmaceuticals Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| GLENMARK | 9.75 | 1.06 | 5.58 | 12.50 | 13.72 | 0.59 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
*Avg of index constituents
Glenmark Pharmaceuticals Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 10.01% | 11.77% | 12.50% | 13.72% |
| FY '20-21 | 7.79% | 23.39% | 13.29% | 13.92% |
| FY '19-20 | 1.82% | -16.30% | 12.05% | 12.64% |
Glenmark Pharmaceuticals Shareholding Pattern
Promoters : 46.65%
FII : 24.12%
DII : 10.96%
Public : 18.27%
Others : 0%
Glenmark Pharmaceuticals Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 10,223.24 | 8,218.98 | 2,394.91 | 1,495.72 |
| FY '20-21 | 9,255.93 | 7,268.57 | 2,210.59 | 1,309.77 |
| FY '19-20 | 8,676.80 | 7,175.64 | 1,884.35 | 1,065.26 |
All values are in crores
Glenmark Pharmaceuticals Share Price
Glenmark Pharmaceuticals Ltd has a significant presence in the branded generics market in all emerging economies including India. The company entered the dermatology market with the launch of Candid cream. Glenmark's pioneering drug development focuses primarily on inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. The company's formulation business focuses on therapeutic areas, e.g. dermatology, infectious medicine, respiratory, cardiac, diabetes, gynecology, central nervous system and oncology. India is the organization's largest market region by revenue.